The model demonstrated that plasma BAFF levels were higher in MS patients treated with IFN-β or immunosuppressants (P = 0.00037 and P = 0.0007, respectively, adjusted for the other confounding factors). This evidence concerns the gene TNFSF13B and myeloid sarcoma.